# Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

> **NCT07147049** · PHASE2 · RECRUITING · sponsor: **Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Moderate to Severe Acute Postoperative Pain

## Interventions

- **DRUG:** HL-1186
- **DRUG:** HL-1186 placebo

## Key facts

- **NCT ID:** NCT07147049
- **Lead sponsor:** Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-08
- **Primary completion:** 2025-12
- **Final completion:** 2026-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07147049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07147049, "Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07147049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*